Abstract. Tumor microenvironment is an important promoter of tumorigenesis in all forms of breast cancer and has been associated with the risk of metastasis in the different breast cancer subtypes including the more frequent luminal subtypes that encompass 60% of cancer patients. Adhesive properties of endothelial cells (ECs) are strikingly affected during cancer cell dissemination and are related to functional changes of adhesion receptors. The contribution of tumor secreted factors to tumor-EC adhesion represents a therapeutic opportunity for breast cancer metastasis. Conditioned medium (CM) of tumor cells can be used as a model to study the role of the secreted molecules to the tumor microenvironment. We explored transcriptomic changes associated to a pro-adhesive phenotype in primary human umbilical vein endothelial cells (HUVECs) treated with CM of the breast cancer cell line ZR75.30 or with TNF for 3 h. Selected genes were used to validate the microarray through RT-qPCR. The bioinformatic analysis identified NFκB as the main regulator of the pro-adhesive phenotype and this was confirmed by pharmacological inhibition of NFκB pathway with BAY 11-7085. The changes induced by ZR75.30-CM mimic those promoted by TNF and display changes in the expression of genes related to inflammatory response, wound healing, extracellular matrix, cytokines, metabolism and cell communication. Despite the abundance of G-CSF, IL-8, IL-6 and VEGF in the ZR75.30-CM and the confirmed activation of STAT3 and VEGFR2 pathways, our results suggest dominance of NFκB as a central controller of the transcriptomic response of ECs to breast cancer cells leading to expression of cell adhesion receptors.
Introduction
Breast cancer is one of the most frequent causes of death among female population worldwide (1) . Metastasis is responsible for >90% of breast cancer mortalities but it is one of the least understood stages of tumor development. Primary luminal A and B subtypes of breast cancer represent 60% of the tumors (2) . From the two luminal subtypes, luminal B is the most aggressive tumor (2, 3) . Following initial clinical response, 40-50% of these patients present recurrence with metastases (4) .
The crucial role of the tumor microenvironment in cancer development and metastasis has recently been highlighted (5) . Virchow provided the first evidence of the interaction between normal tissue and tumor formation, postulating that cancer originates at sites of chronic inflammation (6, 7) .
The tumor microenvironment and chronic inflammation share several soluble molecules, such as cytokines, growth factors and metalloproteases, as well as a variety of distinct cell types, including endothelial cells (ECs) (8) . Recruitment of ECs by tumors is essential in metastasis during tumor vascularization and because they regulate the intra-and extravasation of tumor cells (9) . For a circulating tumor cell to exit the circulatory system (extravasation), it must first bind to a blood vessel wall by one of two mechanisms of arrest: physical occlusion or cell adhesion. The relative prevalence of these mechanisms depends on the biology of the tumor and the diameter of the local post-capillary venule (10) . The extravasation can vary depending on the cancer cell type and the extravasation site Pro-adhesive phenotype of normal endothelial cells responding to metastatic breast cancer cell conditioned medium is linked to NFκB-mediated transcriptomic regulation or target organ, suggesting that it is determined not only by the metastatic potential of the tumor cell, but also by the endothelial response to the unique local endothelial microenvironment (11) . In this process soluble factors derived from both cell types serve in the communication between tumor and ECs. During metastasis, ECs function not simply as static structural cells of perfusing vessels but also as active stromal regulatory cells with privileged access to the tumors (12) . Inflammatory cytokines, including TNF, IL-1, IL-6 and chemokines as IL-8, may also promote adhesion and extravasation by increasing vascular permeability and promoting the survival of tumor cells in the blood circulation. Adherent tumor cells are dependent on chemokine and cytokine gradients to direct their migration through EC monolayers. Several inflammatory cytokines can act at a distance promoting a pro-adhesive phenotype characterized by an increase of adhesion molecules on the apical surface of ECs in target organs. Interestingly, a variety of cytokines can be found in the circulation of cancer patients, and the expression of chemokines and their receptors correlate with the aggressiveness of the tumor (13) . The migratory arrest of cancer cells depends on the quality and quantity of adhesion molecules expressed on ECs, as well as the adhesion molecule repertoire on the cancer cells (9) . In fact, in many cancer types, cell adhesion molecules (CAMs) are frequently associated with metastatic progression and adhesion to EC walls in distant organ sites (14) .
Changes in the gene expression of tumor-associated endothelial cells (TAECs) have been postulated to affect cancer cell fate (15, 16) . Analyzing the contribution of tumor secreted factors to endothelial-recruitment in vivo has proven to be difficult and conditioned medium (CM) secreted by different tumor cell lines have been used as model systems, promoting angiogenesis and a pro-adhesive phenotype in human umbilical vein endothelial cells (HUVECs) as well as TNF (17) (18) (19) . Luminal A and B forms of breast cancer are the most common presentations of the disease and despite the effective treatment; the recurrence in the B subtype is associated with metastasis in most of the patients. Therefore we analyzed the endothelial transcriptome in response to CM from the human luminal B metastatic breast cancer cell line ZR75.30. Bioinformatic analysis implicated NFκB as a key molecular regulator of the vascular pro-adhesive phenotype activated by CM dominating over other cytokine, chemokine and growth factor signaling pathways.
Materials and methods
Cell culture. The breast cancer cell lines MCF-7 (luminal A), ZR75.30 (luminal B) and the monocyte cell line U937 were obtained from ATCC (Manassas, VA, USA) and maintained in RPMI-1640 medium supplemented with 10% FBS (both from Gibco-BRL, Grand Island, NY, USA), penicillin 10,000 U/ml, streptomycin 10 mg/ml and amphotericin B 25 µg/ml (PAA Laboratories GmbH/GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) in a humidified atmosphere of 5% CO 2 at 37˚C.
HUVEC primary culture. HUVECs were isolated and cultured as previously reported (20) by mixing cells from at least three human umbilical cords. The resulting cell cultures were mai ntained in M199 medium (Gibco-BRL) supplemented with 10% FBS, 2 mM L-glutamine (Gibco-BRL), 20 µg/ml endothelial mitogen (Biomedical Technologies, Inc., Stoughton, MA, USA), 5 U/ml heparin (Laboratorios PISA S.A. de C.V), penicillin 10,000 U/ml, streptomycin 10 mg/ml and amphotericin B 25 µg/ml, under a humidified atmosphere of 5% CO 2 at 37˚C. All HUVEC cultures used for the experiments were at the third passage. The local Ethics and Research Committees of the Hospital General Dr Manuel Gea González, Ministry of Health (Mexico) approved this protocol (11-62-2014) , and all participants signed an informed written consent form.
Conditioned medium. CM was isolated as previously described (17) . Briefly, breast cancer cell lines were cultured in 100-mm plates until they reached 80% confluence. The cell layer was first washed 10 times with 10 ml of PBS/RPMI-1640 (1:1 v/v) without phenol red (Laboratorios Microlab S.A. de C.V., D.F. Mexico, Mexico) to remove serum components. Then, cells were maintained in 8 ml of serum-free RPMI without phenol red, after 48 h the culture medium was collected and lyophilized. The resulting powder was dissolved in water (1/10 of the original volume) and dialyzed using a PM-3 Ultrafiltration Membrane (EMD Millipore, Billerica, MA, USA). The solution was filtered through a 0.22-µm Millex-GS syringe filter unit, and a protease inhibitor cocktail was added (cOmplete™ Protease Inhibitor Cocktail; Roche Applied Science, Indianapolis, IN, USA). The protein concentration was determined using the Bradford reagent assay (Bio-Rad, Hercules, CA, USA). The resulting concentrated preparation was maintained at 4˚C until further use.
Bio-Plex assay. CM (50 µl), was analyzed with the Bio-Plex suspension array system (Bio-Rad) against 26 proteins, following the manufacturer's instructions.
Sample treatment. For adhesion assay, microarrays and western blots, confluent HUVECs were treated with 9 µg/ml of the indicated CM or with 10 ng/ml of human recombinant TNF (R&D Systems, Inc., Minneapolis, MN, USA) for the indicated time frames depending on the experiment. At the end of the treatments, the corresponding assay was performed as described. Inhibition of Ikks was performed by pre-incubating HUVECs for 1 h with 10 µM BAY 11-7085 (Calbiochem/Merck kGaA, Darmstadt, Germany). After pre-incubation, HUVECs were stimulated with 9 µg/ml of ZR75.30-CM. Electrophoretic mobility shift assay (EMSA) and IκBα western blotting were performed after 20 min, while CAM western blotting and cell adhesion were evaluated after 3 h, as described. For time course assay, HUVECs were starved 4 h previous to stimulation with 9 µg/ml of ZR75.30-CM, and cell lysates were used for western blot analysis.
Adhesion assay. This assay was performed as previously described (17) , adherent cells were visualized in a TMS-F phase-contrast inverted microscope Nikon Eclipse TS100 (Nikon Instruments, Inc., Melville, NY, USA) and counted in a β counter (1600TR liquid scintillation analyzer; Canberra-Packard, Meriden, CT, USA).
RNA isolation and microarrays. TRIzol reagent (Invitrogen Corp., Camarillo, CA, USA) was used to obtain total RNA from three independent biological replicates of confluent HUVECs (60-mm plates) treated as indicated. The preparation of cRNA hybridization to Human Gene 1.0 ST and data analysis were performed according to Affymetrix™ recommendations. Differentially expressed genes were determined using the Partek ® Genomics Suite software (Partek, Inc., St. Louis, MO, USA) with a p<0.05 and a differential fold change of 1.5 on either positive or negative directions. Gene Ontology (GO) classification was performed through the use of National Cancer Institute-Database for Annotation, Visualization and Integrated Discovery (NCI-DAVID) (http://david.abcc.ncifcrf.gov) (21) and the Search Tool for the Retrieval of Interacting Genes (STRING) software was used to build the functional gene association networks (string-db. org) (22) . Enriched canonical pathways within the networks of differentially expressed genes were carried out using the Ingenuity Pathway Analysis (IPA) (Ingenuity ® Systems; www. ingenuity.com) and Protein ANalysis THrough Evolutionary Relationships (PANTHER) software (www.pantherdb.org) (23) .
RT-qPCR. The generation of cDNA was performed using the First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA) with 2 µg of total RNA as a template. PCR reactions were performed with Maxima SYBR-Green/ROX qPCR Master Mix (Thermo Fisher Scientific, Inc.) on a 7300 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using a conventional amplification protocol. The housekeeping gene ACTIN was used as an internal control. Primer sequences used for gene expression analysis are shown in Table I . The data were analyzed using the 2 -ΔΔCq method (24) . (25) and re-blotted. Optical densitometric scanning was performed using NIH ImageJ software.
Electrophoretic mobility shift assay. Nuclear protein extracts and cytoplasmic fractions from HUVECs and NFκB translocation to the nucleus were determined as previously described (26) . Briefly, 10 µg of the nuclear protein extracts were incubated with γ-32 P-ATP-labeled oligonucleotide containing the consensus NFκB site (5'-AGTTGAGGGGA CTTTCCCAGGC-3') (Santa Cruz Biotechnology, Inc.) in the presence of 100-fold excess of unlabeled specific probe as specific competitor. Samples were fractionated on a 5% non-denaturing polyacrylamide gel in 1X Tris-borate-EDTA buffer and DNA-protein complexes visualized on a Storm PhosphorImager (Molecular Dynamics, San Francisco, CA, USA). For supershift analysis, 1 µg of anti-p65 antibody (Santa Cruz Biotechnology, Inc.) was incubated with the nuclear extract for 30 min at room temperature prior to adding the reaction mixtures. ACTIN  TCCCTGGAGAAGAGCTACGA  AGCACTGTGTTGGCGTACAG  NM_001101  ICAM-1  GACCAGAGGTTGAACCCCAC  GCGCCGGAAAGCTGTAGAT  NM_000201  SELE  CCGAGCGAGGCTACATGAAT  GCATCGCATCTCACAGCTTC  NM_000450  VCAM-1  TGTTTGCAGCTTCTCAAGCTTTTA  GTCACCTTCCCATTCAGTGGA  NM_001078  NFkBIA  CTCCGAGACTTTCGAGGAAATAC  GCCATTGTAGTTGGTAGCCTTCA  NM_020529  CCL20  TGCTGTACCAAGAGTTTGCTC  CGCACACAGACAACTTTTTCTTT  NM_004591  TNFAIP2  GGCCAATGTGAGGGAGTTGAT  CCCGCTTTATCTGTGAGCCC  NM_006291  TRAF1  TCCTGTGGAAGATCACCAATGT  GCAGGCACAACTTGTAGCC  NM_005658  CXCL2  TGCCAGTGCTTGCAGAC  TCTTAACCATGGGCGATGC  NM_002089  PPP1R3C GGTGGCACAGATAGTGATACCT
Statistical analysis. The results are expressed as the means ± SE, and statistical analyses were performed with GraphPad Prism 5.0 software (GraphPad Software, Inc., San Diego, CA, USA). Multiple comparisons were analyzed using one-way ANOVA with Dunnett's post-hoc test and two-way ANOVA with Bonferroni correction. Significance was set at p<0.05.
Results
Differentially expressed genes associated with the pro-adhesive endothelial phenotype induced by ZR75.30-CM. Previous study by our group (18) showed that CM secreted from the breast cancer ZR75.30 cells promotes a pro-adhesive endothelial phenotype. Interestingly, CM secreted from the breast cancer MCF-7 cells did not promote this phenotype nor induced the expression of CAMs: ICAM-1, VCAM-1 and E-selectin, therefore we focus on characterizing the transcriptome of ECs treated with ZR75.30-CM (Fig. 1) .
For the transcriptome analysis a new batch of CM was tested for induction of the pro-adhesive phenotype in ECs and for the content of soluble factors using a multiplex assay. We found enrichment in the inflammatory cytokines TNF, IFN-γ and IL-6, the hematopoietic cytokine G-CSF, the che mokine Control represents basal adhesion of U937 cells to confluent, untreated HUVECs. HUVECs were pre-treated for 3 h with TNF (10 ng/ml), ZR75.30-CM (9 µg/ml) or MCF-7-CM (9 µg/ml) prior to the addition of U937 cells to the HUVEC monolayer. The black arrows indicate U937 cells adhered to HUVECs. The micrographs were taken with x200 magnification. The percentage of U937 cells adhered to HUVECs was obtained as previously described (14) . Data are presented as the means ± SE of the percentage of the total adherent cells in at least three independent experiments. **** p<0.0001. (B) A representative western blotting for ICAM-1, E-selectin and VCAM-1 adhesion molecules employing total HUVEC extracts from cells treated for 3 h with MCF-7-CM (9 µg/ml), ZR75.30-CM (9 µg/ml) or TNF (10 ng/ml). Untreated HUVEC extracts were employed as controls. Actin was used as a loading control. Histograms represent the means (ratio ICAM-1/actin, E-selectin/actin or VCAM-1/actin) ± SE of three independent experiments and are expressed as relative units. * p<0.05, ** p<0.01, *** p<0.001. CM, conditioned medium; CAMs, cell adhesion molecules; HUVECs, human umbilical vein endothelial cells.
IL-8, the growth factor VEGF and, to a lesser extent, the anti-inflammatory cytokine IL-1Ra for ZR75.30-CM. MCF-CM contained lower amounts of these factors. The molecules with the highest differences between ZR75.30-CM and MCF-7-CM were VEGF (>39,592 vs. 14,231 pg/ml), G-CSF (>28,728 vs. 9,594 pg/ml), IL-8 (>24,800 vs. 8,429 pg/ml), IL-6 (2,891 vs. 1,081 pg/ml), IFN-γ (2,068 vs. 1,315 pg/ml) and TNF (1,274 vs. 771 pg/ml). For VEGF, G-CSF and IL-8 from ZR75.30-CM, the values were above of detection range.
Results from the composition analysis were similar to those previously reported (18) . We used TNF as a positive control for the induction of a pro-adhesive endothelial phenotype accompanied by CAM expression. ZR75.30-CM altered the expression of 54 genes in ECs (53 upregulated and 1 downregulated), whereas TNF treatment altered the expression of 299 genes (249 upregulated and 50 downregulated). Of the total number of genes affected, 50 were common to both treatments, 249 were exclusive to the TNF treatment and 4 were exclusive to the ZR75.30-CM treatment (Fig. 2) . Among the 10 genes most upregulated by ZR75.30-CM, are genes related to chemotaxis and inflammation (CCL20, CXCL2, CXCL1, F3, IL-6, IL-8 and TNFAIP3) and cell adhesion (VCAM-1, SELE and RND1). Likewise, the most upregulated genes after TNF treatment correspond to cell adhesion process (VCAM-1, SELE, ICAM-4 and EFNA1), chemotaxis and inflammation (CCL20, CCL5, CXCL2, TNFAIP3 and TNFAIP2) and IFN-γ (IRF1) (Fig. 3A) . All genes affected by both treatments showed significantly higher expression levels with TNF compared to those with ZR75.30-CM with the exception of CXCL2, for which ZR75.30-CM induced higher expression (Fig. 3A) . The genes most repressed by TNF were PPP1R3C, PRICKLE1, ALX1, RUNX1T1, ZNF792, ID2, MBOAT1, ID1, RANBP6 and HOXA9. Interestingly, PPP1R3C showed the strongest downregulation with TNF and it was the only downregulated gene with ZR75.30-CM (Fig. 3B) .
Bioinformatic analysis implicates the NFκB pathway as a central regulator of the gene expression pattern in ECs treated with ZR75.30-CM.
The induction of a pro-adhesive phenotype directed the initial approach of this study, however, the bioinformatic analysis of the microarray by NCI-DAVID software associated the expression profile with other cellular processes such as: inflammatory response (p-values of 1.1e-10 for ZR75.30-CM treatment and 1.2e-11 for TNF), response to wounding (p-value of 4.1e-10 for ZR75.30-CM treatment and 1.3e-11 for TNF) and extracellular space (8.5e-10 for ZR75.30-CM) (Fig. 4A) . While SELE was present in the three processes identified by NCI-DAVID, ICAM-1 and VCAM-1 were present only in the extracellular space process. The genes associated to these processes also shared chemokines, cytokines and components of the NFκB pathway known to regulate and promote a pro-adhesive phenotype (Fig. 4B) .
In a similar analysis using PANTHER software the most representative biological process was the immune system (Fig. 4C) . Among the main pathways identified by IPA software we found granulocyte adhesion and diapedesis (p-value of 1.72e-12) as part of ZR75.30-CM treatment (Table Ⅱ) . NFκB emerged as the principal regulatory molecule with the highest score (p-value of 8.93e-38) in ZR75.30-CM treatment analyzed observed in the microarray analysis was not replicated in the qPCR assays, although their expression level was lower than control for either TNF or ZR75.30-CM treatment (Fig. 6 ). CM plus inhibitor (third and fourth lanes) (Fig. 7B) . Western blotting revealed that the expression of ICAM-1, VCAM-1 and E-selectin increased with ZR75.30-CM treatment and that the expression was prevented when the cells were treated with the inhibitor (third and fourth lanes) (Fig. 7C) . Finally, we confirmed the importance of the NFκB pathway in the adhesion process by showing that the pro-adhesive phenotype induced by ZR75.30-CM was prevented when the cells were treated with the inhibitor (Fig. 7D) .
IPA analysis --------------------------------------------------------------------------------------------------------------------

IPA analysis PANTHER analysis ---------------------------------------------------------------------------------------------------------------
ZR75.30-CM activates early signaling events related to
VEGF and STAT3 pathway. Despite the enrichment in VEGF (>39,592 pg/ml), G-CSF (>28,728 pg/ml), IL-8 (>24,800 pg/ml) and IL-6 (2,891 pg/ml) in ZR75.30-CM that could affect endothelial gene expression through STAT3, microarray analysis did not contain classic target genes related to these pathways. We verified that early signaling events of these systems were not impaired by analyzing the state of phosphorylation at residues related to functional activation of VEGFR2 (Y1175) and STAT3 (Y705) (Fig. 8A) . In response to ZR75.30-CM VEGFR2 phosphorylation presents a biphasic response between 5-180 min. The signal presented a first peak after 5 min that reached a maximum at 30 min and returned to the value of the first peak after 1 h. STAT3 phosphorylation also presented a biphasic response between 5-180 min with a maximum signal at 30 min that became faint close to 120 min. Taken together these results indicate that early signaling of these two systems was not affected. However, when we analyzed the adhesion of HUVECs in response to recombinant human cytokines IL-6 and VEGF the adhesion was not significant (Fig. 8B) .
Discussion
The tumor cell secretome consists of a complex mixture of cytokines and growth factors that contribute to the microenvironment associated with malignancy. These include paracrine and juxtacrine signals that may be involved at virtually any stage of tumorigenesis (27) . These tumor soluble factors contribute to recruiting normal stromal cells into actions that favor tumorigenesis, such as normal ECs for the intra-and extravasation processes relevant in metastatic dissemination. Hematogenic dissemination of metastatic cells ends once the tumor cells attach to ECs in the target organs. Following adhesion to the apical membrane of the ECs, successful metastasis requires extravasation followed by metastatic cell proliferation in the stroma. In cell adhesion and extravasation many ligand-receptor interactions contribute to these processes, the endothelial repertoire of CAMs involved includes: selectins, integrins, cadherins, CD44 and members of the superfamily of CAMs (28) . How normal cells integrate and priorize the information of a mixture of molecules present in the tumor microenvironment in vivo has been difficult to approach. However, treatment of normal or cancer cells with CM has been a useful strategy to perform this kind of studies (29) . Considering that pro-inflammatory cytokines can induce a pro-adhesive endothelial phenotype, we postulated that the endothelial transcriptome associated to this phenotype induced by tumor secreted factors from the ZR75.30 breast cancer cell line could be similar to that induced by pro-inflammatory cytokines.
Microarray analysis was applied to further characterize this pro-adhesive endothelial state. Bioinformatic analysis with NCI-DAVID identified overlapping gene ontology profiles associated to inflammatory response, wound healing and extracellular space that was consistent with immune system and cell communication processes identified by PANTHER analysis. NFκB was identified as the principal molecular regulator by both IPA and PANTHER analysis. STRING gene interaction network analysis confirmed NFκB as a central hub related to CAMs and also revealed its connection with NFκB through IL-6, IL-8, CCL2 and CCL20. Interestingly CCL20 was the third highest gene expressed in response to ZR75.30-CM and the highest in response to TNF (Fig. 3) .
These findings suggest that the EC expression profile in response to CM includes a group of genes associated to a transcriptome induced by inflammatory cytokines and moreover, this response appears to be regulated by NFκB.
TNF is recognized as a classic inducer of a pro-adhesive endothelial phenotype through NFκB activation (30-32) ; however, IL-6, IL-8, IFN-γ and VEGF can also promote indirect NFκB activation (33) (34) (35) . Early STAT3 phosphorylation was confirmed in response to ZR75.30-CM indicating intact signaling capacity (Fig. 8A) . Similarly, the signaling activity of VEGF present in ZR75.30-CM was confirmed when we followed the phosphorylation state of VEGFR2 (Fig. 8A) . However, these cytokines did not induce a significant pro-adhesive response compared to ZR75.30-CM or TNF (Fig. 8B) . The NFκB-dependent transcription appears to be dominant over other transcription-initiating pathways after 3 h and shows a partial overlap with VEGF-dependent transcriptome in HUVECs at 0.5-6 h of exposure to VEGF. The genes shared between VEGF and ZR75. 30 (36) . In the case of VEGF transcriptome related to endothelial proliferation is probably a later event in time (24 h) and are therefore absent at the time point analyzed (3 h). In contrast, IL-6 and IL-8 pathways appear in our bioinformatic analysis (positions 28 and 45, respectively) with p<e-12. In fact, crosstalk between NFκB/STAT3 and NFκB/VEGF pathways has been reported (35, 37) suggesting that a signaling crosstalk converged through NFκB gene expression in our model, perhaps which might priorize gene expression of this master regulator. A similar transcriptional dominance was reported in lymphatic ECs treated with MDA-MB231-CM were, the STAT3 activation prevailed (29) .
The transcriptome induced in ECs by ZR75.30-CM shares 93% of its transcripts with TNF. Only four genes (7%) were exclusive to the ZR75.30-CM treatment: KIAA1199, PKD1L1, SORBS1 and TGFB3. In breast cancer, increase of KIAA1199 expression correlated with hypomethylation and NFκB binding in the KIAA1199 regulatory region (38) . In contrast, KIAA1199 repression in colon cancer cells attenuates the Wnt pathway and reduces proliferation (39) . Chimeric products of PKD1L1 with RIF1 have been identified in breast cancer cells (40) . The function of SORBS1 is related to lipid anabolism and this protein is also associated with FAk and is a substrate of the c-Abl tyrosine kinase (41) . TGFB3 is important in cellular differentiation and development, and in ECs, this isoform participates in homeostasis and maintenance when cells are subjected to shear stress (42) . Hence, SORBS1 and TGFB3 appear to represent specific genes related to changes in cellular behavior that promote intercellular interactions.
Although the bioinfor matic analysis indicates TNF/NFκB-activated pathway, only 50 of the 299 genes affected by recombinant TNF responded to ZR75.30-CM treatment (Fig. 3) , suggesting that concomitant stimulation with the mixture restricted the expression pattern. The majority of the overlapping genes had the highest fold change with the TNF treatment. Among the genes repressed by TNF, the phosphatase PPP1R3C had the highest score, and was the only gene repressed in response to ZR75.30-CM treatment. IPA analysis indicates that the repression of this phosphatase is linked to TNF. Overall, the expression changes induced by ZR75.30-CM have a smaller magnitude than those induced by TNF.
There are several microarrays of ECs treated with different cytokines and growth factors. These treatments include TNF (31, 43) , IL-1 (44) and VEGF (36, 45) ; however, expression profiles of ECs treated with IL-6, IL-8 and IFN-γ are scarce, and transcriptome data for ECs exposed to components of the tumor microenvironment are even more limited. A recent study in TAECs identified 49 genes to be associated with chronic inflammation diseases and cancer; 6 of them constituted an inflammation-related endothelial-derived gene signature (IREG) (46) . Of these 49 genes TNFAIP3 was the only one shared with ZR75.30-CM treatment. We found the gene variant IRF1, which is related to the IRF7 variant from the IREG. We also identify inflammation-related diseases (Table Ⅱ) as well as TNF and members of the NFκB family to be central regulators (Table Ⅲ) .
We validated expression changes in 14 of the 54 genes altered by ZR75.30-CM. Several of the validated genes are important endothelial physiological mediators and have also been associated with tumorigenesis and malignancy in a variety of cancer models (Table Ⅳ) .
Among the validated genes are the CAMs ICAM-1, E-selectin and VCAM-1 whose expression has been used as marker of pro-adhesive endothelial phenotype. Expression of these three cell adhesion molecules has been associated to tumorigenesis and malignancy (47) (48) (49) .
The bioinformatic analysis of microarrays in the present study indicates that NFκB is a central regulator of the pro-adhesive phenotype of HUVECs induced by breast cancer secreted factors (Fig. 9) . To further verify the physiological and molecular relevance of NFκB, we used BAY 11-7085, a specific inhibitor of IKKs, to interfere with this pathway. We had previously shown that interference with NFκB activation in ECs treated with CM from human leukemia prevents NFκB activation and cell adhesion (17) . The fact that we obtained similar results with CM from a different neoplastic such as breast cancer suggests that NFκB-dependent activation may be common to epithelial and hematopoietic neoplastic diseases.
In conclusion, the endothelial transcriptome related to the pro-adhesive phenotype induced by secreted factors from ZR75.30 breast cancer cells reveals inflammatory mediators and NFκB as essential regulators of this phenotype, and pharmacological inhibition of NFκB validated this prediction. Since all these changes occur in primary non-transformed human ECs, and this response is performed by a mixture of cytokines and growth factors like those secreted by tumor cells, interfering with dominant transcription pathways could be an alternative therapeutic strategy to interfere with metastasis.
